Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 4Phase 3 3Phase 4 2Phase 1 2Phase NA 1

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Pancreatic Neoplasms 74Carcinoma, Non-Small-Cell Lung 73Breast Neoplasms 39Lung Neoplasms 31Urinary Bladder Neoplasms 28Nasopharyngeal Carcinoma 28Ovarian Neoplasms 25Neoplasm Metastasis 21Cholangiocarcinoma 18Triple Negative Breast Neoplasms 16Neoplasms 16Lymphoma, Large B-Cell, Diffuse 13Gallbladder Neoplasms 13Biliary Tract Neoplasms 13Uterine Cervical Neoplasms 12Recurrence 12Carcinoma, Transitional Cell 12Nasopharyngeal Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Fallopian Tube Neoplasms 10Non-Muscle Invasive Bladder Neoplasms 9Lymphoma 7Carcinoma 7Bile Duct Neoplasms 7Lymphoma, Non-Hodgkin 6Adenocarcinoma 6Carcinoma, Hepatocellular 5Adenocarcinoma of Lung 5Neoplasms by Site 4Urothelial Cancer 3

Interventions

Vincristine 7Cyclophosphamide 710-propargyl-10-deazaaminopterin 7Prednisone 6Doxorubicin 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5romidepsin 3belinostat 3Gemcitabine 3liposomal doxorubicin 2duvelisib 1Vitamin B 12 1MLN 8237 1Folic Acid 1Etoposide 1E7777 fusion protein 1Decitabine 1CHOP protocol 1Brentuximab Vedotin 1Bendamustine Hydrochloride 1BAEC protocol 1Alemtuzumab 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, T-Cell, Peripheral × Gemcitabine × Clear all
NCT06522737 2026-04-06

TERZO

SecuraBio

Phase 3 Recruiting
124 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral

NCT07234162 2025-11-18

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

Dizal Pharmaceuticals

Phase 3 Recruiting
218 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT01482962 2018-07-31

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Takeda

Phase 3 Completed
271 enrolled 25 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡